GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

This is a multicenter, randomized, open-label, controlled Phase 2 study in patients with unresectable hepatocellular carcinoma (uHCC). The purpose of this study is to compare the efficacy and safety of GKL-006 Injection in combination with transarterial chemoembolization (TACE) versus TACE alone.

Trial Details

NCT ID
NCT07209813
Phase
PHASE2
Sponsor
Beijing Gene Key Life Technology Co., Ltd
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • GKL-006 Injection
  • TACE
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Changsha, Hunan, China|28.19874,112.97087
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Voluntarily participates in the study and provides written informed consent.
  • Male or female, age ≥ 18 and ≤ 80 years old
  • Has pathologically, cytologically, or radiologically confirmed unresectable hepatocellular carcinoma.
  • Has CNLC stage II to IIIa disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →